Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1134018

registered interest
date	24/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accelerated Access Collaborative
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will list the (a) criteria and (b) timelines for products to be considered in (i) the current round and (ii) future review rounds of the Accelerated Access Collaborative route.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	268506
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:12:14 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1134019

registered interest
date	24/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accelerated Access Collaborative
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how products selected by the Accelerated Access Collaborative will be funded.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	268507
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>As announced in the Life Sciences Sector Deal 2, up to £2 million of Pathway Transformation Funding has been made available to support the use and integration of product selected by the Accelerated Access Collaborative (AAC) into every day practice within the National Health Service. In addition, four of the seven technology areas currently receiving AAC support have been selected to be funded by NHS England through the Innovation and Technology Payment programme (ITP). The ITP aims to remove financial and procurement barriers to support the NHS to adopt innovative medical devices, diagnostics, and digital products.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:07:33 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1134020

registered interest
date	24/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accelerated Access Collaborative
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether all products considered by the Accelerated Access Collaborative will have to be cost-neutral to the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	268508
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>As it continues to drive forward the assessment and uptake of the best products for support, the Accelerated Access Collaborative (AAC) has been empowered to be flexible and pragmatic enough to identify truly game-changing innovations, that may not be cost-neutral in year, but are assessed by the National Institute for Health and Care Excellence to be both clinically and cost-effective. This will allow the AAC to identify products, or classes of products, that are most likely to significantly transform care in the National Health Service.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:06:04 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon